BioSpace News Archive

Hepatocellular carcinoma is the most common primary liver malignancy, accounting for 75% to 80% of liver cancers worldwide.

Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotechnology company, announced the appointment of Dr. Mark J. Gilbert as Chair of its Scientific Advisory Board – leading a team of cell and gene therapeutics experts as scientific advisors to the company.

Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer.

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), today announced receipt of U.S. Food and Drug Administration (“FDA”) study may proceed letter for a Phase 1 study under the Company’s Investigational New Drug application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.

A paper outlining consensus disease definitions for neurological toxicities in cancer patients undergoing immune checkpoint inhibitor treatment was published this week in the Journal for ImmunoTherapy of Cancer (JITC) by a team of physicians at 16 institutions (https://pubmed.ncbi.nlm.nih.gov/34281989/).

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), today announced that it will host a conference call on Wednesday, August 4, 2021 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2021 and to provide a corporate update.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, August 3, 2021.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.